• Pulsar 18 T3
  • Pulsar 18 T3

    Pulsar®-18 T3

    A unique combination of 3 technologies

    Pulsar-18 T3 is indicated for use to improve luminal diameter in patients with symptomatic de novo, restenotic, or occlusive lesions located in the superficial femoral or proximal popliteal arteries, with reference vessel diameters from 3.0 to 6.0 mm and total lesion lengths up to 190 mm.*

    Category

    Vascular Intervention Peripheral Stent Systems

    Product Highlights

    Thin struts, low COF

    Low profile delivery system

    Tri-axial system with braided shaft

    Tri-axial system with braided shaft

    Accurate stent deployment

    Unique tri-axial shaft design

    The outer stabilizing shaft isolates the retractable shaft from friction caused by the introducer valve to ensure accurate stent deployment

    Pulsar 18 T3

    Low profile delivery system

    Smaller puncture site area1

    4F low profile - improved acute outcomes* vs. 6F³

    4F low profile - improved acute outcomes* vs. 6F³

    Potential for safer, faster and simpler procedures than 6F
    • Clinically proven lower access site complication rates³
    • Shorter compression time³
    • 45% smaller puncture site than 6F¹
    • No need for a closure device³
    • Potential for ambulatory treatment
    45%
    smaller puncture site than 6F¹

    Thin struts, low COF

    Lower risk of restenosis2

    140 μm thin struts - thinner than leading brands¹

    Thinner struts for lower Chronic Outward Force (COF)1

    Thinner struts and lower COF make a difference:*

    • Lower risk of restenosis2
    • Reduced vessel injury and inflammation2
    • Faster endothelialization4,5

    Clinical Highlights

    Product Overview

    Pulsar-18 T3

    Pulsar 18 T3

    Technical Data

    Stent
    Catheter type OTW
    Recommended guide wire 0.018”
    Stent material Nitinol
    Strut thickness 140 μm
    Strut width

    85 μm
    Stent coating proBIO® (Amorphous Silicon Carbide)
    Stent markers 6 gold markers each end
    Sizes ø 4.0 - 7.0 mm; L:20 - 200 mm
    Shaft 4F, hydrophobic coating, tri-axial
    Usable length 90 cm and 135 cm

    Ordering Information

      Stent 

    ø (mm)

    Catheter length 90 cm 

    (Stent length mm)
        20** 30 40 60 80 100 120 150 170 200
    4F 4 430437 430438 430439 430440 430441 430442 430443 430444 430445 430446
    5 430447 430448 430449 430450 430451 430452 430453 430454 430455 430456
    6 430457 430458 430459 430460 430461 430462 430463 430464 430465 430466
    7 430467 430468 430469 430470 430471 430472 430473 430474 430475 430476
    **8 weeks pre-order only
      Stent 

    ø (mm)

    Catheter length 135 cm

    (Stent length mm)
        20** 30 40 60 80 100 120 150 170 200
    4F 4 430477 430478 430479 430480 430481 430482 430483 430484 430485 430486
    5 430487 430488 430489 430490 430491 430492 430493 430494 430495 430496
    6 430497 430498 430499 430500 430501 430502 430503 430504 430505 430506
    7 430507 430508 430509 430510 430511 430512 430513 430514 430515 430516
    **8 weeks pre-order only

    Downloads and Related Links

    Downloads

    Download Brochure Download IFU Endovascular Today Supplement - Maximizing results for SFA stenting Endovascular Today Supplement - Expert cases on CTO management Download US Vascular Intervention Product Catalog

    Related Links

    Newsroom More information about Pulsar-18 T3

    How can we help you?

    I prefer to be contacted by
    *Fields are mandatory.

    References

    FTLR = Freedom from Target Lesion Revascularization.

    1. BIOTRONIK data on file; 2. Zhao HQ. Late stent expansion and neointimal proliferation of oversized nitinol stents in peripheral arteries. Cardiovasc Intervent Radiol. 2009 Jul;32(4):720-6; 3. Bosiers M et al. 4-French – compatible endovascular material is safe & effective in the treatment of femoropopliteal occlusive disease: Results of the 4EVER Trial. ENDOVASC THER 2013; 20: 746-756; 4. Koskinas C. Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation. JACC 2012 10;59(15):1337-49; 5. Koppara T. Thrombogenicity and early vascular healing response in metallic biodegradable polymer-based and fully bioabsorbable drug-eluting stents. Circ Cardiovasc Interv. 2015 8(6):e002427; 6. Funovics M. Correlation between chronic outward force (COF) and neointimal hyperplasia in self-expanding nitinol stents in swine in clinically relevant oversizing ranges. Presented at: LINC, Jan 26, 2017; Leipzig, Germany, 7. Bosiers M. 4EVER 24 month results: long-term results of 4F Pulsar stent in femoropopliteal lesions. Presented at: CIRSE 2013; Barcelona, Spain; 8. Lichtenberg M. Superficial Femoral Artery TASC D registry: 12-month effectiveness analysis of the Pulsar-18 SE nitinol stent in patients with critical limb ischemia. J Cardiovasc Surg (Torino). 2013 Aug; 54(4):433-9; 9. Lichtenberg et al. Effectiveness of the Pulsar-18 self-expanding stent with optional drug-coated balloon angioplasty in the treatment of femoropopliteal lesions - the BIOFLEX PEACE All-Comers Registry.Vasa (2019), 1-9. doi_10.10240301-1526a000785.

    *Indication as per IFU. Pulsar and proBIO are trademarks or registered trademarks of the BIOTRONIK Group of Companies.